Sodium Phenylacetate

Summary

Sodium Phenylacetate (CHEMBL1200358) is an approved small molecule; indicated across 2 conditions including central nervous system neoplasm and brain disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 158.13 Da · C8H7NaO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200358
Name	Sodium Phenylacetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	23690424
Molecular formula	C8H7NaO2
Molecular weight	158.13
InChIKey	HZOREEUASZHZBI-UHFFFAOYSA-M

SMILES: C1=CC=C(C=C1)CC(=O)[O-].[Na+]

IUPAC name: sodium 2-phenylacetate

Also known as: NSC-3039, Sodium phenylacetate, Sodium phenylacetic acid, SODIUM PHENYLACETATE, SID538568

Patent coverage: 2,465 distinct patent families (10,401 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
brain disorder	2	MONDO:0005560	HP:0001298

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004767	PHASE2	COMPLETED	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).